Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Safety Study of Allogeneic MSCs for Burn Wounds
NCT02104713Phase 1Completed
- Start
- Jun 2014
- Primary completion
- Mar 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MSV alogénicas in burn injury. Primary endpoint: Adverse Events as Assessed by CTCAE v4.0 at 1.5 years. Started Jun 2014; status: completed.
02
Drugs
MSV alogénicas
03
Conditions
burn injury
Beyond the preview
Go deeper on NCT02104713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02104713.